Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label TrialSikander Ailawadhi, Yifan Zhai, Mary C. Collins et al.|Clinical Cancer Research|2023Cited by 38
First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).Sikander Ailawadhi, Yifan Zhai, Asher Chanan‐Khan et al.|Journal of Clinical Oncology|2021Cited by 25